Avivagen Inc. (VIV.V)

0.0050 0.0000 (0.00%) At close: 10:30AM EDT

Avivagen Inc.

100 Sussex Drive
Ottawa, ON K1A 0R6
Canada
613-702-2908
https://www.avivagen.com

Sector(s): Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. G. F. Kym Anthony	CEO & Vice Chairman	361.06k	N/A	1956
Dr. Graham Burton Ph.D.	Co-Founder, Chief Scientific Officer & Director	126.33k	N/A	N/A
Mr. Ira Levy	Interim Chief Financial Officer	120.38k	N/A	N/A
Dr. James Nickerson Ph.D.	President and Executive VP of Business Development & Product Innovation	N/A	N/A	N/A
Mr. Drew Basek	Director of Investor Relations	N/A	N/A	N/A
Ms. Tracy Gillett BVSC	Director of Companion Animal & Marketing Manager	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Avivagen Inc. focuses on developing and commercializing products for livestock feeds that support immune function and help animals to achieve their growth and productivity. The company offers OxC-beta Livestock, a premix for inclusion in livestock feeds; Vivamune health chews for dogs; Dr. Tobias dog chews; and Dr. Tobias Beta blend for the human immune system. It serves in Canada, Mexico, Brazil, the Philippines, Taiwan, and Thailand. Avivagen Inc. was incorporated in 2005 and is headquartered in Ottawa, Canada.

Corporate Governance

Avivagen Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.